CDC is building an approach to the surveillance of neurologic conditions in three stages. Stage 3 is dependent upon resources.
COVID-adjusted dates show delays caused by extensive deployments of staff to support CDC’s ongoing COVID-19 response. However, progress has also been gained in terms of access to additional data sources as well as efficiencies in receiving data due to CDC’s COVID-19 response and Data Modernization Initiative.
Stage 1: Learn What Works
Conduct demonstration projects of two high-burden neurological conditions: multiple sclerosis (MS) and Parkinson’s disease (PD).
- Identify, assess, and select data sources and case definitions.
- Use case definitions in data sources to produce initial MS and PD prevalence estimates.
- Propose approaches for NNCSS build out and extension.
Initial Plan: October 2018 to September 2020
COVID-adjusted: October 2018 to August 2023
Stage 2: Build Out NNCSS
Implement approaches to enable ongoing surveillance of MS and PD.
- Maintain surveillance of MS and PD prevalence and add other priorities (for example, mortality).
- Add data sources and refine approaches and cost estimates.
- Explore criteria to help prioritize conditions to add to NNCSS.
Initial Plan: October 2020 to September 2021
COVID-adjusted: January 2022 to September 2023
Stage 3: Extend NNCSS
Implement approaches to initiate surveillance of additional neurological conditions.
- Use NNCSS approaches to produce surveillance estimates for new conditions.
- Continue surveillance for MS and PD.
- Review data sources, methods, and approaches to ensure they remain state-of-the-art.
Initial Plan: October 2021 and beyond
COVID-adjusted: September 2024 and beyond